Professor of Clinical Medicine
Vice Chair of Clinical Oncology, Orange County Program
Is this your profile? Click to edit
Phone +1 323 226 7593
Email louis.vandermolen@med.usc.edu
Overview
Dr. VanderMolen earned his medical degree from Loyola University Stritch School of Medicine. He performed his Internal Medicine Internship and Residency from Baylor College of Medicine- Texas Medical Center. He then went on to complete two fellowships, the first in hematology at Baylor, and the second in oncology at National Cancer Institute- Clinical Oncology Program.
Awards
- Orange County Medical Association: Physician of Excellence Award, 2006-2013
- Baylor College of Medicine: Chief Resident, Internal Medicine, 1983-1984
- Phi Beta Kappa: Elected Member, 1977
Publications
- Should high-dose interleukin-2 still be the preferred treatment for patients with metastatic melanoma? Cancer Biother Radiopharm. 2012 Aug; 27(6):337-43.. View in PubMed
- A retrospective study of induction chemotherapy with docetaxel, cisplatinum, and 5-fluorouracil followed by concurrent radiotherapy with cetuximab in locally advanced head and neck cancer Am J Otolaryngol. 2012 Jan-Feb; 33(1):93-7. . View in PubMed
- Should high-dose interleukin-2 still be the preferred treatment for patients with metastatic renal cell cancer? Cancer Biother Radiopharm. 2011 Jun; 26(3):273-7.. View in PubMed
- High-dose chemotherapy and autologous stem cell rescue for metastatic breast cancer: superior survival for tandem compared with single transplants Am J Clin Oncol. 2005 Jun; 28(3):281-8. . View in PubMed
- Autologous tumor cell line-derived vaccine for patient-specific treatment of advanced renal cell carcinoma Cancer Biother Radiopharm. 2004 Oct; 19(5):570-80. . View in PubMed
- Does continuous-infusion interleukin-2 increase survival in metastatic melanoma? Am J Clin Oncol. 2003 Apr; 26(2):141-5.. View in PubMed
- Successful treatment of transitional cell carcinoma of the urethra with chemotherapy Cancer Invest. 2002; 20(2):206-7. . View in PubMed
- Treatment of kidney cancer with autologous tumor cell vaccines of short-term cell lines derived from renal cell carcinoma Cancer Biother Radiopharm. 2001 Feb; 16(1):47-54. . View in PubMed
- Profile of the pediatric endocrine clinic at New York-Presbyterian Hospital, New York Weill Cornell Center J Clin Endocrinol Metab. 1999 Dec; 84(12):4444-9. . View in PubMed
- Hybrid high-dose bolus/continuous infusion interleukin-2 in patients with metastatic melanoma: a phase II trial of the Cancer Biotherapy Research Group (formerly the National Biotherapy Study Group) Cancer Biother Radiopharm. 1997 Aug; 12(4):249-55. . View in PubMed
- Phase I study of subcutaneously administered interleukin-2 in combination with interferon alfa-2a in patients with advanced cancer J Clin Oncol. 1996 Aug; 14(8):2234-41. . View in PubMed
- Malignant melanoma and pregnancy ten questions West J Med. 1996 Feb; 164(2):156-61. . View in PubMed
- The integration of high-dose chemotherapy and biotherapy: initial 5-year experience with autologous bone marrow transplantation in a comprehensive community cancer center Cancer Biother. 1995; 10(1):25-36. . View in PubMed
- High-dose carboplatin and recombinant granulocyte-macrophage colony-stimulating factor in advanced-stage recurrent ovarian cancer J Clin Oncol. 1993 Nov; 11(11):2118-26. . View in PubMed
- Primary lymphoma of the kidney: complete remission after systemic chemotherapy J Natl Cancer Inst. 1993 Mar 17; 85(6):505-6. . View in PubMed
- Pilot study of interleukin-2 and lymphokine-activated killer cells combined with immunomodulatory doses of chemotherapy and sequenced with interferon alfa-2a in patients with metastatic melanoma and renal cell carcinoma J Natl Cancer Inst. 1992 Jun 17; 84(12):929-37. . View in PubMed
- Intraperitoneal lymphokine-activated killer-cell and interleukin-2 therapy for malignancies limited to the peritoneal cavity J Clin Oncol. 1990 Oct; 8(10):1618-29. . View in PubMed
- Surface light chain phenotype in indolent lymphomas: lack of prognostic significance Am J Hematol. 1990 May; 34(1):15-20. . View in PubMed
- Erythrocytosis in hairy cell leukaemia following therapy with interferon alpha Br J Haematol. 1990 May; 75(1):133-5. . View in PubMed
- Recombinant human granulocyte-macrophage colony-stimulating factor in patients with advanced malignancy: a phase Ib trial J Natl Cancer Inst. 1990 Apr 18; 82(8):697-703. . View in PubMed
- Low- versus high-dose interferon alfa-2a in relapsed indolent non-Hodgkin’s lymphoma J Natl Cancer Inst. 1990 Feb 07; 82(3):235-8. . View in PubMed
- Diffuse osteosclerosis in hairy cell leukemia Blood. 1989 Nov 01; 74(6):2066-9. . View in PubMed
- Adrenal insufficiency and interleukin-2 therapy Ann Intern Med. 1989 Jul 15; 111(2):185. . View in PubMed
- Hypothyroidism after interleukin-2 therapy J Clin Oncol. 1989 May; 7(5):686-7. . View in PubMed
- Lactic acidosis in lymphoma: prompt resolution of acidosis with therapy directed at the lymphoma J Natl Cancer Inst. 1988 Sep 07; 80(13):1077-8. . View in PubMed
- Ringed sideroblasts in primary myelodysplasiaLeukemic propensity and prognostic factors. Arch Intern Med. 1988 Mar; 148(3):653-6. . View in PubMed
- Torsade de pointes: an unusual manifestation of chloral hydrate poisoning Am Heart J. 1986 Jul; 112(1):181-4. . View in PubMed
- Plasma cell dyscrasia with marrow fibrosisClinicopathologic syndrome. Am J Med. 1985 Sep; 79(3):297-302. . View in PubMed
- Multiple myeloma in a hom*osexual man with chronic lymphadenopathy Arch Intern Med. 1985 Apr; 145(4):745-6. . View in PubMed
